Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLDYanlin Zhu(Xiamen University), Yong Li(Second Affiliated Hospital of Xi'an Jiaotong University)Frontiers in PharmacologyMay 14, 202010.3389/fphar.2020.00590Cited by 21SaveCiteExport RISWatch citationsRelated PapersPHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS|Shock|2015|50MicroRNA-142-3p alleviated high salt-induced cardiac fibrosis via downregulating optineurin-mediated mitophagy|iScience|2024|9Epidemiological Features of Sinonasal Adenocarcinoma and Prognostic Nomogram: A Study Based on the SEER Database|Cancer Control|2025|0